SOURCE: Daxor Corp.

March 17, 2008 10:24 ET

Daxor Announces Publication of Clinical Study Demonstrating Blood Volume Analysis Benefits Critically Ill Surgical Patients

NEW YORK, NY--(Marketwire - March 17, 2008) - Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced the publication in the Hawaii Medical Journal of "Circulating Blood Volume Measurements Correlate Poorly with Pulmonary Artery Catheter Measurements," which demonstrated clinical benefit of the Blood Volume Analyzer BVA-100 to critically ill surgical patients.

In this pilot study, twenty critically ill surgical intensive care unit (SICU) patients who had been admitted to Queen's Medical Center, Honolulu, HI, had their fluid management treatment changed 21% of the time due to Daxor's Blood Volume Analyzer. Treatment changes resulted in patients experiencing clinical improvements in cardiac, pulmonary and/or kidney function.

The Queen's SICU medical team was asked to determine patient volume status by conventional parameters such as pulmonary artery catheter (PAC) measurements and Blood Volume Analysis (BVA) with Daxor's Blood Volume Analyzer BVA-100. The BVA results were utilized to guide fluid management therapy. The BVA altered treatment was compared to conventional surrogate methods to discover if patients benefited from the BVA guided treatment.

Prior to BVA, fluid management in the SICU has historically been based on surrogate measurements like the PAC despite data from several previous clinical trials showing that the PAC is a poor reflection of a patient's response to fluids. In this study, the PAC showed weak statistical agreement with BVA.

The patients in this study had respiratory failure, severe septic shock and hemorrhagic shock. Diagnosing and treating intravascular blood volume in these patients is critical. The investigators of this study noted that, "Measuring pressure to infer volume continues to be problematic. Furthermore, circulating BVA provides distinct measurement of disturbances in the red blood cell volume and the plasma volume. This precise information, resulting in treatment targeted at improving each individual component of total blood volume, is not obtainable from pressure measurements provided by the pulmonary artery catheter."

Additional larger studies are on-going at Queen's Medical Center and other medical institutions to further demonstrate clinical efficacy of a BVA in critically ill and other chronic and acute medical conditions.

Daxor Corporation manufactures and markets the BVA-100, the only FDA-approved semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com.

Contact Information

  • Contact Information:

    Stephen Feldschuh
    Chief Operating Officer
    212-330-8515
    Email Contact

    Diane Meegan
    Investor Relations
    212-330-8512
    Email Contact